In the next five years, we anticipate increased research on the development of biomarker-guided treatment strategies targeting AURKA and PLK1 related pathways, driven by advances in precision oncology approaches, a better understanding of immune-metabolic signaling pathways, and high-resolution profiling of tumor biology. Here, PLK1 is linked to neoplasm.